Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.

Author: ElassalJoe, GerberRobert, KereiakesDean J, LeporNorman E, Michael GibsonC, ThompsonDesmond, Veronica LeeL

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the efficacy and safety of alirocumab, a PCSK9 inhibitor, in patients with atherosclerotic cardiovascular disease (ASCVD) with or without prior coronary revascularization. The results demonstrated that alirocumab effectively reduced LDL-cholesterol levels and was well tolerated in this patient population.
Paper Details　
Original Abstract of the Article :
Patients with atherosclerotic cardiovascular disease (ASCVD) and prior revascularization are at high risk of further cardiovascular events and may require additional lipid-lowering therapies beyond maximally tolerated statin therapy. We assessed the efficacy and safety of alirocumab, a proprotein co...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.atherosclerosis.2018.07.010

データ提供：米国国立医学図書館（NLM）

Alirocumab: A New Weapon in the Fight Against Cardiovascular Disease?

The field of cardiovascular disease is constantly seeking new and effective treatments to reduce the risk of heart attacks, strokes, and other serious cardiovascular events. This study investigates the efficacy and safety of alirocumab, a PCSK9 inhibitor, in patients with atherosclerotic cardiovascular disease (ASCVD) with or without prior coronary revascularization.

A New Oasis in the Desert of Cardiovascular Disease

The researchers conducted a pooled analysis of eight phase 3 trials, evaluating the effectiveness of alirocumab in a broad range of patients with ASCVD. The results suggest that alirocumab, when added to maximally tolerated statin therapy, significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with ASCVD, regardless of whether they had undergone prior coronary revascularization. This finding is significant, as it suggests that alirocumab may offer a valuable therapeutic option for a broad population of patients at high risk for cardiovascular events. It's like finding a hidden oasis in the vast desert of cardiovascular disease – alirocumab may provide a new and effective way to protect patients from the devastating effects of this condition.

A Promising New Therapy

This study highlights the potential of alirocumab as a promising new therapy for a broad range of patients with ASCVD. The drug's ability to significantly reduce the risk of MACE, even in patients with prior coronary revascularization, is a significant advancement in the field of cardiovascular medicine.

Dr.Camel's Conclusion

This research offers a beacon of hope in the fight against cardiovascular disease. Just as a camel navigates a challenging desert landscape, researchers are constantly seeking new and effective ways to protect patients from this devastating condition. The study's findings suggest that alirocumab may be a valuable addition to the arsenal of treatments for ASCVD, offering a new and promising path towards better cardiovascular health for patients at risk.

Date :
  1. Date Completed 2019-12-10
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

30025648

DOI: Digital Object Identifier

10.1016/j.atherosclerosis.2018.07.010

Related Literature

Article Analysis
・Effects of alirocumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.